Indian equities are poised for a positive shift as falling crude oil prices ease inflation and currency concerns, according to Sundaram Mut...

Telangana is charting a new course to elevate Hyderabad into a global drug discovery hub. The state is fostering an integrated ecosystem by...

Indian equities ended lower, snapping a two-day rally as escalating Iran-US tensions and profit booking weighed on sentiment. Sensex fell 3...

It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...

Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...

Indian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...

Raamdeo Agrawal recalls Rakesh Jhunjhunwala’s exceptional ability to spot undervalued stocks and build long-term wealth, highlighting his f...

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

Indian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...

Indian markets experienced profit booking, falling over a percent amidst a weak global trend. Key stocks like Vedanta, Honasa Consumer, IRC...

Indian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...

Investor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

India's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...